基于PET/CT的分期策略对头颈部鳞状细胞癌患者生存的预测强于标准影像策略
该前瞻性队列研究纳入307例组织学确诊的头颈部鳞状细胞癌患者,同日行胸部X线+头颈MRI、胸部CT+头颈MRI及18F-FDG PET/CT分期。PET/CT较标准影像显著改变肿瘤分期分层,基于PET/CT的分期与死亡风险差异显著相关,总体判别能力C指数0.712优于CXR/MRI的0.675和CCT/MRI的0.657。
要点
- PET/CT较CXR/MRI或CCT/MRI显著改变HNSCC肿瘤分期分层(χ2检验P<0.001)。
- 仅基于PET/CT的分期在Kaplan-Meier分析中与死亡风险差异显著相关(P≤0.002)。
- PET/CT总体判别能力C指数0.712,显著优于CXR/MRI的0.675(P=0.04)和CCT/MRI的0.657(P=0.02)。
核心结论
- 基于PET/CT确定的肿瘤分期较标准影像策略确定的肿瘤分期在生存方面具有更明显的预后区分特性。
研究设计与样本
- 采用基于配对数据的盲法前瞻性队列研究,于2013年9月至2016年3月在欧登塞大学医院连续招募组织学确诊的原发性头颈部鳞状细胞癌(HNSCC)患者。
- 所有患者在同一天接受胸部X线+头颈MRI(CXR/MRI)、胸部CT+头颈MRI(CCT/MRI)及18F-FDG PET/CT检查。
- 肿瘤分为局限期(I和II期)、局部晚期(III和IVB期)或转移期(IVC期),共纳入307例患者。
主要发现
- PET/CT较CXR/MRI或CCT/MRI均显著改变肿瘤分期分层(χ2检验,两者P<0.001)。
- 基于PET/CT的分期在Kaplan-Meier分析中与死亡风险差异显著相关(所有基于PET/CT的比较P≤0.002),而基于CXR/MRI或CCT/MRI的分期未显示此关联。
- 总体判别能力C指数PET/CT为0.712,显著高于CXR/MRI的0.675(P=0.04)和CCT/MRI的0.657(P=0.02)。
- PET/CT较CXR/MRI的净重分类改善为0.184(P=0.03),较CCT/MRI的净重分类改善为0.094%(P=0.31)。
关键数值与推荐
- 肿瘤分期标准:局限期(I和II期)、局部晚期(III和IVB期)、转移期(IVC期)。
- 判别能力评价指标:Harrell C指数、Kaplan-Meier分析、Cox比例风险回归及净重分类改善。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Our purpose was to examine whether staging of head and neck squamous cell carcinoma (HNSCC) by upfront 18F-FDG PET/CT (i.e., on the day of biopsy and before the biopsy) discriminates survival better than the traditional imaging strategies based on chest x-ray plus head and neck MRI (CXR/MRI) or chest CT plus head and neck MRI (CCT/MRI). Methods: We performed a masked prospective cohort study based on paired data. Consecutive patients with histologically verified primary HNSCC were recruited from Odense University Hospital from September 2013 to March 2016. All patients underwent CXR/MRI, CCT/MRI, and PET/CT on the same day. Tumors were categorized as localized (stages I and II), locally advanced (stages III and IVB), or metastatic (stage IVC). Discriminative ability for each imaging modality with respect to HNSCC staging were compared using Kaplan-Meier analysis, Cox proportional hazards regression with the Harrell C-index, and net reclassification improvement. Results: In total, 307 patients with histologically verified HNSCC were included. Use of PET/CT significantly altered the stratification of tumor stage when compared with either CXR/MRI or CCT/MRI (χ2, P < 0.001 for both). Cancer stages based on PET/CT, but not CXR/MRI or CCT/MRI, were associated with significant differences in mortality risk on Kaplan-Meier analyses (P ≤ 0.002 for all PET/CT-based comparisons). Furthermore, overall discriminative ability was significantly greater for PET/CT (C-index, 0.712) than for CXR/MRI (C-index, 0.675; P = 0.04) or CCT/MRI (C-index, 0.657; P = 0.02). Finally, PET/CT was significantly associated with a positive net reclassification improvement when compared with CXR/MRI (0.184, P = 0.03) but not CCT/MRI (0.094%, P = 0.31). Conclusion: Tumor stages determined by PET/CT were associated with more distinct prognostic properties in terms of survival than those determined by standard imaging strategies.
引用
- Rohde M, Nielsen AL, Pareek M, et al. A PET/CT-Based Strategy Is a Stronger Predictor of Survival Than a Standard Imaging Strategy in Patients with Head and Neck Squamous Cell Carcinoma. J Nucl Med. 2017. PMID: 28864630. doi:10.2967/jnumed.117.197350
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。